PRZOOM - /newswire/ -
Palo Alto, CA, United States, 2006/06/07 - New analysis from Frost & Sullivan finds that the U.S. Infectious Disease Diagnostics Markets, as defined in the research service, earned revenues of $3.8 billion in 2005 and estimates this to reach $6.4 billion in 2012..
Infectious diseases present significant public health problems. Molecular tests, immunoassays, and culture-based tests offer different aspects of the solution.
New analysis from Frost & Sullivan finds that the U.S. Infectious Disease Diagnostics Markets, as defined in the research service, earned revenues of $3.8 billion in 2005 and estimates this to reach $6.4 billion in 2012.
If you are interested in a virtual brochure, which provides manufacturers, end users, and other industry participants an overview of the latest analysis of the U.S. Infectious Disease Diagnostics Markets, then send an e-mail to Melina Trevino - Corporate Communications at melina.trevino[.]frost.com with the following information: your full name, company name, title, telephone number, e-mail address, city, state, and country. We will send you the information via email upon receipt of the above information.
“The cost and labor pressures that are inherent in today’s U.S. clinical laboratory are driving the adoption of automated high throughput testing methods,” says Frost & Sullivan Research Analyst Martin Nejat. “Moreover, the need for more rapid testing methods is compelling increase usage of rapid molecular assays.”
Market participants are responding to these pressures through the development and validation of new molecular assays and immunoassays. An increasing number of healthcare facilities are acquiring molecular capability because of decentralization in diagnostic testing.
However, the high initial capital investment in equipment, training, and validation is too costly for many laboratories. The lack of awareness among clinicians with regard to molecular tests further hinders adoption.
“Molecular tests require specialized training to interpret and implement the test results. Many clinicians simply do not have the appropriate training with regard to the features and benefits of these tests. For example, a recent physician survey indicated that physicians have questions about the meaning of viral loads, how to monitor them, and what changes from the baseline are significant. Lack of awareness and understanding of molecular tests among clinicians is a significant restraint for this market throughout the forecast period,” says Nejat.
U.S. clinical laboratories require a custom solution that takes into account their particular challenges. Testing volume, geographic variation in reimbursement rates, and medical focus of laboratory’s physician base are factors that are considered by successful market participants.
U.S. Infectious Disease Diagnostics Markets is part of the Clinical Diagnostics, which also includes research in the following markets: U.S. Molecular Diagnostics Markets, U.S. Genetic Diagnostics Markets, U.S. Rapid Microbiology Tests Markets, and the U.S. Infectious Diseases: Sexually Transmitted IVD Markets. All research included in subscriptions provide detailed market opportunities and industry trends that have been evaluated following extensive interviews with market participants. Interviews are available to the press.
Frost & Sullivan, a global growth consulting company, has been partnering with clients to support the development of innovative strategies for more than 40 years. The company's industry expertise integrates growth consulting, growth partnership services, and corporate management training to identify and develop opportunities. Frost & Sullivan serves an extensive clientele that includes Global 1000 companies, emerging companies, and the investment community by providing comprehensive industry coverage that reflects a unique global perspective and combines ongoing analysis of markets, technologies, econometrics, and demographics.
U.S. Infectious Disease Diagnostics Markets (F728-55)